Kura Oncology's Strategic Developments and Partnership With Kyowa Kirin Justify Buy Rating, Despite Initial Stock Dip

TipRanks06:28 ET · Ratings

Jefferies Adjusts Kyowa Kirin's Price Target to 3,000 Yen From 3,700 Yen, Keeps at Buy

MT Newswires01:59 ET · Ratings

Express News | Kura Oncology Shares Are Trading Lower. The Company Announced It Entered Into a Global Strategic Collaboration With Kyowa Kirin to Develop and Commercialize Ziftomenib

BenzingaNov 21 10:53 ET

Kura Teams Up With Kyowa Kirin To Develop Ziftomenib, Secures $330 Mln Upfront

RTTNewsNov 21 07:25 ET

Strategic Partnership With Kyowa Kirin Strengthens Kura Oncology's Financial and Commercial Position

TipRanksNov 21 07:15 ET

Kura Oncology Partners Kyowa Kirin to Advance AML Treatment

Yahoo FinanceNov 21 06:37 ET